D. Boral Capital Reaffirms "Buy" Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX - Get Free Report)'s stock had its "buy" rating reiterated by D. Boral Capital in a note issued to investors on Monday,Benzinga reports. They presently have a $2.00 price target on the stock. D. Boral Capital's target price suggests a potential upside of 108.33% from the stock's previous close.

Several other brokerages have also recently weighed in on LCTX. B. Riley reduced their price target on Lineage Cell Therapeutics from $4.00 to $3.00 and set a "buy" rating on the stock in a research note on Friday, March 14th. HC Wainwright reissued a "buy" rating and issued a $9.00 target price on shares of Lineage Cell Therapeutics in a report on Monday. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $4.20.

Lineage Cell Therapeutics Price Performance

NYSEAMERICAN LCTX opened at $0.96 on Monday. Lineage Cell Therapeutics has a 1 year low of $0.37 and a 1 year high of $1.19. The business's 50-day moving average is $0.58 and its 200 day moving average is $0.61. The stock has a market capitalization of $219.23 million, a PE ratio of -12.08 and a beta of 1.51.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Fort Sheridan Advisors LLC raised its stake in shares of Lineage Cell Therapeutics by 71.5% in the fourth quarter. Fort Sheridan Advisors LLC now owns 55,177 shares of the company's stock worth $28,000 after buying an additional 23,000 shares during the period. HighTower Advisors LLC grew its position in Lineage Cell Therapeutics by 49.5% in the fourth quarter. HighTower Advisors LLC now owns 57,706 shares of the company's stock worth $29,000 after acquiring an additional 19,100 shares in the last quarter. Atria Wealth Solutions Inc. purchased a new position in Lineage Cell Therapeutics during the fourth quarter worth $29,000. Two Sigma Advisers LP raised its position in Lineage Cell Therapeutics by 312.2% in the 4th quarter. Two Sigma Advisers LP now owns 86,964 shares of the company's stock worth $44,000 after purchasing an additional 65,864 shares during the period. Finally, Squarepoint Ops LLC bought a new stake in Lineage Cell Therapeutics in the fourth quarter worth about $46,000. 62.47% of the stock is owned by hedge funds and other institutional investors.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.